Cargando…

Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)

Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoran, Wu, Jibiao, Wang, Bin, Liu, Cun, Liu, Lijuan, Sun, Changgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521627/
https://www.ncbi.nlm.nih.gov/pubmed/36129152
http://dx.doi.org/10.3892/ijo.2022.5424
_version_ 1784799882972758016
author Ma, Xiaoran
Wu, Jibiao
Wang, Bin
Liu, Cun
Liu, Lijuan
Sun, Changgang
author_facet Ma, Xiaoran
Wu, Jibiao
Wang, Bin
Liu, Cun
Liu, Lijuan
Sun, Changgang
author_sort Ma, Xiaoran
collection PubMed
description Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immune checkpoint blockades results in only a small fraction of patients benefiting from the treatment. An increasing number of preclinical studies have reported that PD-L1 expression in tumor cells is involved in a number of epigenetic changes, including histone modifications, non-coding RNA regulation and DNA methylation. In addition, multiple epigenetic targeting drugs have been demonstrated to directly or indirectly interfere with PD-L1 expression in various cancer models. This provides opportunities to better characterize the regulatory mechanisms of PD-L1 expression and explore novel therapeutic strategies to improve immunosuppressant response rates and overcome drug resistance. The present review focuses on the latest findings and evidence on the epigenetic mechanism regulating PD-L1 expression and discusses the biological and clinical implications of this regulatory mechanism in solid tumors. A rational combination of epigenetic regulation and PD-1/PD-L1 axis blockade may improve the prognosis of patients with solid tumors.
format Online
Article
Text
id pubmed-9521627
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-95216272022-09-30 Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) Ma, Xiaoran Wu, Jibiao Wang, Bin Liu, Cun Liu, Lijuan Sun, Changgang Int J Oncol Articles Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immune checkpoint blockades results in only a small fraction of patients benefiting from the treatment. An increasing number of preclinical studies have reported that PD-L1 expression in tumor cells is involved in a number of epigenetic changes, including histone modifications, non-coding RNA regulation and DNA methylation. In addition, multiple epigenetic targeting drugs have been demonstrated to directly or indirectly interfere with PD-L1 expression in various cancer models. This provides opportunities to better characterize the regulatory mechanisms of PD-L1 expression and explore novel therapeutic strategies to improve immunosuppressant response rates and overcome drug resistance. The present review focuses on the latest findings and evidence on the epigenetic mechanism regulating PD-L1 expression and discusses the biological and clinical implications of this regulatory mechanism in solid tumors. A rational combination of epigenetic regulation and PD-1/PD-L1 axis blockade may improve the prognosis of patients with solid tumors. D.A. Spandidos 2022-09-20 /pmc/articles/PMC9521627/ /pubmed/36129152 http://dx.doi.org/10.3892/ijo.2022.5424 Text en Copyright: © Ma et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Ma, Xiaoran
Wu, Jibiao
Wang, Bin
Liu, Cun
Liu, Lijuan
Sun, Changgang
Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
title Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
title_full Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
title_fullStr Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
title_full_unstemmed Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
title_short Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
title_sort epigenetic modifications: critical participants of the pd-l1 regulatory mechanism in solid tumors (review)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521627/
https://www.ncbi.nlm.nih.gov/pubmed/36129152
http://dx.doi.org/10.3892/ijo.2022.5424
work_keys_str_mv AT maxiaoran epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview
AT wujibiao epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview
AT wangbin epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview
AT liucun epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview
AT liulijuan epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview
AT sunchanggang epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview